Artificial intelligence (AI) has the potential to change that, but not because it automates work. The greatest opportunity for AI is helping scientists, clinicians, and business leaders make better decisions throughout the development lifecycle.
Across conversations with pharmaceutical executives, AI leaders, regulators, and researchers, four shifts are beginning to reshape how medicines will be developed over the next decade.
1. From Automation to Reinvention
Most organizations are using AI to automate yesterday's workflows. That's an important first step—but it isn't transformation. The greatest opportunity is fundamentally rethinking how drug development works.
Today's clinical development model was built for an era of limited data, linear experimentation, and sequential decision-making. AI allows us to challenge those assumptions. Instead of waiting years to validate a hypothesis, researchers can now model, simulate, and refine decisions before a clinical trial even begins, reducing uncertainty before the first patient is enrolled.
This shift is about far more than efficiency. Every better decision made upstream has the potential to prevent costly late-stage failures, accelerate promising therapies, and ultimately improve outcomes for patients waiting for new treatment options.
Organizations that use AI to optimize existing workflows will become more efficient. Organizations that use it to reinvent the way medicines are developed will define the future of drug development.
2. From Predictions to Continuous Decision Intelligence
For decades, drug development has been built around a series of isolated decisions -- will this trial succeed, endpoint be met, patient population respond? Each decision was made with limited information and then locked in place for months, or even years, until new data became available. Then, maybe a decade later, we found out if that decision was right or wrong.
But diseases don't progress in snapshots, and neither should the decisions that shape how we develop medicines.
AI is making it possible to move beyond one-time predictions toward continuous decision intelligence. By integrating clinical, biological, operational, and real-world data, organizations can make decisions at the start, backed by evidence, and then continually refine their understanding of risk, probability, and opportunity as evidence evolves.
Instead of making a handful of high-stakes decisions throughout development, teams can make smarter decisions at the start – before a trial begins – and then continuously during -- adapting protocols, refining patient populations, and improving trial strategies before uncertainty becomes costly.
The future isn't simply better predictions. It's a fundamentally better way of making decisions.
3. From Humans in the Loop to Experts in the Loop
Much of the conversation around AI has centered on keeping "humans in the loop." That's an important safeguard -- but in drug development, it's not enough.
First, until recently, I went along with the industry and used the term "humans in the loop." However, over recent months, I've come to realize that this term undersells the expertise of the clinical development teams within biopharma. At QuantHealth, we believe the more accurate description is "experts in the loop" – a cycle in which experts train, test, and validate the technology; in which in-house experts make decisions and act as authorities in their field; and in which, collectively, everyone touching biopharma – partners and in-house teams alike – becomes smarter and more experienced.
This is an important nuance because drug development has never been the work of a single expert. Every major decision draws on the collective expertise of clinicians, statisticians, biologists, regulatory leaders, data scientists, commercial teams and now, AI partners. The challenge isn't replacing human judgment—it's bringing these perspectives together quickly enough to make the best possible decisions.
This is where AI creates its greatest value. Not by replacing experts, but by connecting them. AI can synthesize vast amounts of scientific, clinical, operational, and real-world data, giving multidisciplinary teams a shared understanding of risk, opportunity, and evidence before critical decisions are made.
The organizations that lead the next era of drug development won't remove humans from decision-making. They'll create environments where AI accelerates collaboration, while experts provide the judgment, context, and accountability that no model can replace.
The future isn't humans versus machines. It's experts and AI working together to make decisions that neither could make alone.
4. From Linear Development to Continuous Optimization
For decades, clinical development has followed a familiar sequence: Design, Execute, Analyze, and Learn. That model made sense when evidence could only be generated through long, sequential clinical studies. But waiting years to discover whether a critical decision was the right one is becoming increasingly difficult to justify.
Advances in simulation, predictive modeling, real-world data, and adaptive AI are creating the possibility of a fundamentally different approach: one where development becomes a continuous cycle of prediction, validation, and refinement.
Instead of discovering problems after hundreds of millions of dollars have been invested, organizations can identify risk earlier, refine trial strategies before execution, and redirect resources toward the programs most likely to succeed. This is important because it creates a future when:
The future of drug development won't be defined by faster execution: it will be defined by continuous optimization.
The Next Generation of Drug Development
These four shifts point toward something larger than AI: they represent a new operating model for pharmaceutical R&D.
The organizations that lead the next decade won't simply generate more data or deploy more AI, they will build cultures capable of making better decisions faster. That means moving beyond automation, isolated AI tools, and incremental improvement to being those that combine predictive intelligence, scientific expertise, and continuous learning to fundamentally rethink how medicines are developed.
That's not simply the next chapter of AI -- it's the next chapter of drug development.